Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
Sigma Pharmaceuticals Limited	15 088 417 403

We (the entity) give ASX the following information.

Information about buy-back

1 Type of buy-back On-market buy-back

2 Date Appendix 3C was given to 13 September 2012 ASX

Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

	Before previous of		day Previous day		
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	61,203,101	175,000		
4	Total consideration paid or payable for the shares/units	\$44,113,699	\$101,623		

		Before p	oreviou	s day	Previous day	
5	If buy-back is an on-market buy- back	Highest \$0.8525	price	paid:	Highest price pa \$0.5850	id:
		Lowest	prico	noid	Lowest price pa \$0.5700	id:
		\$0.5650	price	•		

How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

57,252,251

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

(Director/Company secretary)

SUE MORGAN

Date: 23 October 2013

Print name:

== == == == ==